Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 10, 2011, Pages 3087-3094

  Kappers, Mariëtte H W ^a   Van Esch, Joep H M ^a   Smedts, Frank M M ^a   De Krijger, Ronald R ^a   Eechoute, Karel ^a   Mathijssen, Ron H J ^a   Sleijfer, Stefan ^a   Leijten, Frank ^a   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a   Visser, Theo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LIOTHYRONINE; SUNITINIB; THYROID HORMONE; THYROTROPIN; THYROXINE; TYPE 3 DEIODINASE; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MICROANGIOPATHY; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; RETROSPECTIVE STUDY; THYROID CAPILLARY REGRESSION; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CAPILLARIES; CARCINOMA, RENAL CELL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOTHYROIDISM; INDOLES; IODIDE PEROXIDASE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PYRROLES; RATS; RATS, INBRED WKY; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

ANIMALIA; RATTUS;

EID: 80053470531     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1172     Document Type: Article

References (29)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
2. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R 2007 Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373 (Pubitemid 46450424)
3. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev 6:219-228
4. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672
5. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, Braun D, Schweizer U, Arnold R, Dörken B, le Coutre P 2010 Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 20:1209-1214
6. Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, Kurokawa M 2011 Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol 93:400-402
7. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 28:515-519
8. De Groot JW, Links TP, van der Graaf WT 2006 Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17:1719-1720 (Pubitemid 44680895)
9. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576
10. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664 (Pubitemid 46768841)
11. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K 2011 The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104:241-247
12. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L 2007 A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534 (Pubitemid 47435331)
13. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH 2010 Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56:675-681
14. Kester MH, Toussaint MJ, Punt CA, Matondo R, Aarnio AM, Darras VM, Everts ME, De Bruin A, Visser TJ 2009 Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver. Endocrinology 150:540-545
15. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83
16. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448-454
17. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338 (Pubitemid 44528723)
18. Schoeffski P, Wolter P, Himpe U, Dychter SS, Baum C, Prenen H, Wildiers H, Bex M, Dumez H 2006 Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 24(18S):3092
19. Shaheen PE, Tamaskar IR, Salas RN, Rini BI, Garcia J, Wood L, Dreicer R, Bukowski RM 2006 Thyroid function tests abnormalities in patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 24(18S):4605
20. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355
21. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635 (Pubitemid 351918450)
22. Thorin E, Webb DJ 2010 Endothelium-derived endothelin-1. Pflugers Arch 459:951-958
23. Chanoine JP, Braverman LE, Farwell AP, Safran M, Alex S, Dubord S, Leonard JL 1993 The thyroid gland is a major source of circulating T3 in the rat. J Clin Invest 91:2709-2713 (Pubitemid 23182526)
24. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, Da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA 2008 Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 118:975-983 (Pubitemid 351364605)
25. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV 2010 Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29:2938-2949
26. Bello G, Ceaichisciuc I, Silva S, Antonelli M 2010 The role of thyroid dysfunction in the critically ill: a review of the literature. Minerva Anestesiol 76:919-928
27. Warner MH, Beckett GJ 2010 Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 205:1-13
28. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228-238 (Pubitemid 38082818)
29. Garfield D, Hercbergs A, Davis P 2007 Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol 4:674